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Abstract 
Long-chain fatty acid oxidation deficient patients present early in life with more severe features than patients with a medium-chain 
fatty acid oxidation deficiency. This may be related to the more toxic effect of long-chain fatty acid derivatives. In this paper we have 
studied the effect of different acyl-CoA esters, and palmitoyl-CoA in particular, on succinate-driven oxidative phosphorylation, using 
digitonin permeabilized human fibroblasts. Palmitoyl-CoA was found to inhibit the succinate-driven oxidative phosphorylation in a 
concentration dependent manner. If the inhibition of the oxidative phosphorylation system is also expressed under in vivo conditions this 
might explain some of the abnormalities found in patients with defects in long-chain fatty acid /3-oxidation. 
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1. Introduction 
Fatty acids are an essential metabolic fuel, specially at 
times of stress or prolonged fasting [1]. Most of the fatty 
acids which are supplied for catabolism have a chain 
length of 12-20 carbon atoms. The complete oxidation of 
fatty acids in mitochondria nvolves four consecutive steps 
including entry into the cell via a mechanism not well 
understood, activation in the cytosol to acyl-CoA esters, 
transport across the mitochondrial membrane via a carni- 
tine shuttle (carnitine palmitoyi transferase I (CPT I), 
carnitine/acylcarnitine translocator and carnitine palmitoyi 
transferase II (CPT II)) and finally intramitochondrial /3- 
oxidation. Although /3-oxidation in principle requires four 
consecutive reactions including dehydrogenation, hydrata- 
tion, dehydrogenation again and thiolytic cleavage, there 
are multiple enzymes for each /3-oxidation step. For in- 
'Abbreviations: PBS, phosphate-buffered saline; Hepes, (N-[2- 
hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]); NCS, newborn calf 
serum; MES, 2-morpholinoethane sulfonic acid; MOPS, 3-(N-morpho- 
lino)propane sulfonic acid 
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stance, four straight-chain acyl-CoA dehydrogenases have 
been identified in mitochondria with specificity for short- 
chain, medium-chain, long-chain and very-long-chain fatty 
acyl-CoA esters [2,3]. Furthermore, multiple enoyl-CoA 
hydratases, 3-hydroxyacyl-CoA dehydrogenases and thio- 
lases have been identified too [2,3]. Medium and short- 
chain fatty acids do not need the carnitine shuttle, since 
they appear to enter the mitochondria directly being acti- 
vated in the mitochondrial matrix. 
Recently an increasing number of inherited isorders of 
fatty acid metabolism have been identified [3] with defects 
at the level of the cellular uptake of carnitine (primary 
systemic arnitine deficiency) [4,5], CPT I and II [6,7], the 
carnitine/acylcarnitine translocator [8], short-chain acyl- 
CoA dehydrogenase (SCAD) [9], medium-chain acyl-CoA 
dehydrogenase (MCAD) [10], long-chain acyl-CoA dehy- 
drogenase (LCAD) [11], very-long-chain acyl-CoA dehy- 
drogenase (VLCAD) [12,13] and long-chain 3-hydroxy- 
acyl-CoA dehydrogenase (LCHAD) [14], electron transfer 
flavoprotein (ETF) and finally ETF-dehydrogenase [ 15,16] 
(for a review see [3]). It should be pointed out that all 
patients formerly thought o suffer from LCAD deficiency 
are in fact deficient in VLCAD [12,13]. 
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Among the various disorders known up to now, MCAD 
deficiency is probably the most frequent. Affected patients 
show a wide spectrum of signs and symptoms [17,18]. 
MCAD-deficient patients may present early in life with a 
clinical presentation resembling Reye's syndrome with 
major hepatic involvement, sometimes rapidly culminating 
into sudden death. On the other hand, MCAD deficiency 
may also occur in asymptomatic ndividuals [19]. Avail- 
able evidence suggests that the prognosis of MCAD defi- 
ciency may be relatively good provided that diagnosis is 
early and treatment initiated immediately [18]. 
(V)LCAD deficiency has only been described in a few 
patients and is usually more severe than MCAD defi- 
ciency, with earlier age at initial presentation, striking 
evidence for cardiac (cardiomegaly) [20,21] and skeletal 
muscle involvement, prolonged residual hypotonia [20], 
later evidence of exercise induced muscle dysfunction and 
evidence for an acute and residual hypertrophic cardiomy- 
opathy [12,13,20,21]. (V)LCAD deficiency is associated 
with death in early infancy [17] even when diagnosed and 
treated immediately. 
Patients with a defect in long-chain fatty acid /3-oxida- 
tion either at the level of (V)LCAD or LCHAD are usually 
lethargic, with severe to mild lactic acidosis [20,22,23], 
unexplained episodes of cardiorespiratory arrest 
[ 13,21,22,24] and coma [13,22-24], with recurrent episodes 
of hypoketotic hypoglycaemia and dicarboxylic aciduria 
especially after prolonged periods of fasting [13,20,22-28], 
Hepatomegaly is a frequent finding in affected patients. 
One of the abnormalities frequently observed is the macro- 
and microvesicular hepatic fat infiltration [17,22-24,27]. 
Skeletal muscle is very often involved, with myopathy 
[13,21,27] and development of a chronic muscle weakness 
[12,22-26,28]. 
As described above, there are marked differences in the 
clinical presentation of long-chain fatty acid oxidation 
deficient patients and MCAD-deficient patients, which may 
well have to do with the more toxic nature of long-chain 
acyl-CoA esters compared to medium-chain acyl-CoA es- 
ters. One frequent finding in long-chain fatty acid oxida- 
tion disorders (but not MCAD-deficient patients) [20,22,23] 
is a moderate to severe lactic acidemia which might be 
explained by a disturbance in the oxidative phosphoryla- 
tion system or any other step in pyruvate oxidation. In this 
paper we have studied the effect of different acyl-CoA 
esters on succinate-driven oxidative phosphorylation using 
a recently described system consisting of digitonin-per- 
meabilized fibroblasts [29]. 
2. Materials and methods 
2.1. Cell culture conditions 
Human skin fibroblasts from control individuals were 
cultured as described before [29,30]. After reaching conflu- 
ency the cells were washed several times with PBS and 
harvested with Trypsin-EDTA as described elsewhere 
[29,30]. The action of trypsin was stopped by adding 
HAM-F10 medium supplemented with 15% (v/v)  NCS, 
20 mM Hepes and antibiotics (l%-Penicillin/Strepto- 
mycin). The content of the flasks was centrifuged at 
337 X g~v (5 rain, 25 ° C). The pellet obtained was resus- 
pended in 10 ml of cell culture medium (HAM-FI0 plus 
15% NCS) and cells were allowed to recover for 30 rain at 
room temperature. After centrifuging at 337 X g~v (5 min, 
25 ° C), the cells were washed twice and finally resus- 
pended in 0.9% NaCI. 
The protein content was measured using bicinchoninic 
acid [31]. Fibroblast stock solutions were diluted to give 2 
mg protein per ml. 
2.2. Measurement of ATP and malate ,£vnthesis in perme- 
abilized fibroblasts 
Measurement of ATP synthesis in permeabilized fibrob- 
lasts was essentially as described by Wanders et al. [29]. 
Human skin fibroblasts were incubated at a final concen- 
tration of 0.4 mg/ml, in a standard medium containing 
150 mM KCI, 25 mM Tris-HCl buffer (pH 7.4), 2 mM 
EDTA, 10 mM potassium phosphate buffer (pH 7.4), 0.1% 
(w/v) bovine serum albumin, 1 mM ADP, 40 ~g/ml  
digitonin (optimal concentration asestablished before [29]), 
0.02 mg/ml rotenone and 10 mM succinate as respiratory 
substrate. 
Different acyl-CoA esters were added to the reaction 
medium from stock solutions prepared in 20 mM 
MES/NaOH (pH 6.0) at the concentrations indicated in 
the Figures. 
Incubations were allowed to proceed for 30 min at 
25°C and the reactions topped with 2 N perchloric acid 
(final concentration 0.5 N). After 15 min on ice-water, 
tubes were centrifuged at 10000 X gav (6 rain, 4°C) and 
the supernatants neutralized to pH 6-7 with 2 M potas- 
sium hydroxide/0.6 M MOPS. The ATP produced was 
measured fluorimetrically according to standard proce- 
dures [32]. In the same samples malate was also measured 
following a standard procedure [33]. 
2.3. Citrate synthase latency measurements in permeabi- 
lized fibroblasts 
The integrity of the mitochondrial membrane in perme- 
abilized cultured skin fibroblasts incubated with different 
concentrations of palmitoyl-CoA (0-100/zM) was studied 
by measuring the latency of citrate synthase. To this end 
human skin fibroblasts (prepared as described above) were 
incubated at a final concentration of 0.4 mg/ml in a 
mixture containing 150 mM KC1, 25 mM Tris-HCl buffer 
(pH 7.4), 2 mM EDTA, 10 mM potassium phosphate 
buffer (pH 7.4), 40 /xg/ml digitonin, 0.1% bovine serum 
albumin (essentially fatty acid free) plus 1 mM oxaloac- 
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etate and 1 mM acetyl-CoA as substrates for citrate syn- 
thase. 
Different concentrations of palmitoyl-CoA were added 
as described above. Incubations were performed for 30 
min at 25°C and reactions topped by rapidly heating the 
samples (10 min in a boiling water bath). After cooling for 
15 min in ice water the tubes were centrifuged at 10000 × 
gav (6 min, 4°C). In the protein-free supernatants he 
citrate was measured spectrophotometrically fo lowing the 
method described by Stitt [34]. In some experiments he 
effect of palmitoyl-CoA on citrate synthase was tested 
using skin fibroblasts either disrupted by ultrasonic disrup- 
tion (3 cycles of 15 s with 45 s intervals, 8 W) or by 
addition of detergent (Triton X-100, final concentration 
0.1%). Incubations were performed as described above. 
2.4. Materials 
All the reagents for cell culture were obtained from 
Gibco-BRL. Hepes, bicinchoninic acid, bovine serum albu- 
min, MOPS, rotenone, were purchased from Sigma (St. 
Louis, USA). The respiratory substrates, acetyl-CoA and 
the fatty acyl-esters were obtained from the same source. 
The protein standards were obtained from Oxford (St. 
Louis, USA). Triton X-100 was obtained from Bio-Rad 
(California, USA). ADP, ATP, APAD, NAD(P)(H) and all 
the enzymes were purchased from Boehringer (Mannheim, 
Germany). All other reagents were of analytical grade. 
3. Results 
We studied the effect of palmitoyl-CoA on the synthesis 
of ATP, using digitonin to permeabilize control human 
fibroblasts thus making the mitochondria accessible to all 
components in the incubation medium. Succinate was used 
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Fig. I. Succinate-driven synthesis of ATP in digitonin-permeabilized 
fibroblasts as a function of time in the absence ( I )  and presence of 
palmitoyl-CoA (tS) (15 /zM). Data represent the mean value of two 
different incubations within a single experiment. Similar results were 



















Fig. 2. Effect of different concentrations of palmitoyl-CoA on succinate- 
driven synthesis of ATP from ADP and phosphate in permeabilized 
fibroblasts. Values are the means of seven separate xperiments per- 
formed in duplicate. For experimental details see Section 2. 
tion. Furthermore, rotenone was added to inhibit complex I 
and thereby fatty acid oxidation. Incubations were carried 
out in a cytosol-mimicking medium in the absence of 
L-carnitine to block uptake of added palmitoyl-CoA. 
Fig. 1 shows that synthesis of ATP is linear with time 
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Fig. 3. Effect of palmitoyl-CoA (A) and 2,4-dinitrophenol (B) on the 
formation of ATP ( • ) and L-malate ( [] ) in permeabilized cells. Incuba- 
tions were performed for 30 rain exactly as described in Section 2. Values 
are the means of two separate xperiments performed in duplicate. 
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palmitoyl-CoA (15 /zM). Based on these results all subse- 
quent experiments were performed for 30 rain. Fig. 1 
further shows that ATP-synthesis is much slower in the 
presence of palmitoyl-CoA (15 /zM). 
Fig. 2 shows the effect of increasing concentrations of
palmitoyl-CoA on ATP synthesis. The results show that 
ATP synthesis is progressively inhibited by increasing 
concentrations of palmitoyl-CoA with full inhibition at 50 
/xM and halfmaximal inhibition at about 15-20 /zM pal- 
mitoyl-CoA. 
In Fig. 3 we studied whether the inhibitory effect of 
palmitoyl-CoA on respiratory-chain driven oxidative phos- 
phorylation (Figs. 1 and 2) may be due to an uncoupler-like 
effect. To this end we repeated the experiment of Fig. 2 
and compared the effects of palmitoyl-CoA and 2,4- 
dinitrophenol (DNP), an established uncoupler of oxidative 
phosphorylation. Apart from the synthesis of ATP the 
production of L-malate was also measured, since this is a 
good estimate of the rate of succinate oxidation per so. Fig. 
3 shows that ATP synthesis was progressively inhibited by 
DNP whereas L-malate production was not affected, which 
sharply distinguishes between the effects of palmitoyl-CoA 
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Fig. 4. Effect of palmitoyl-CoA (A) and Triton X-100 (B) on the latency 
of citrate synthase in digitonin-permeabilized fibroblasts (11) and in 
fibroblasts disrupted by sonication ([]). The maximal ctivity for citrate 
synthase in sonicated cells was the same as in 0.1% (w/v) Triton X-100 
treated cells. Values are means of two separate experiments performed in 

















0 50 100 150 200 









0 50 100 150 200 
Rate of ATP synthesis (%) 
Fig. 5. Effect of different saturated (A) and unsaturated (B) acyl-CoA 
esters and palmitoyl-L-carnitine (A) on succinate-driven oxidative phos- 
phorylation. Values represent the mean of 1-7 separate experiments, 
depending on the acyl-CoA studied, performed in duplicate. Abbrevia- 
tions used: c, cis; t, trans. 
creased by palmitoyl-CoA in much the same way as ATP 
synthesis. 
The effect of palmitoyl-CoA on ATP and malate syn- 
thesis could also be attributed to a possible detergent-like 
effect of this long-chain acyl-CoA ester. To check for the 
detergent activity of palmitoyl-CoA, we studied the effect 
of palmitoyl-CoA on the latency of citrate synthase. The 
latter parameter is a good measure to assess the integrity of 
the mitochondrial inner membrane. To this end digitonin 
permeabilized cells were incubated in the standard medium 
supplemented with oxaloacetate and acetyl-CoA, the sub- 
strates for citrate synthase. The inner membrane of the 
mitochondria is impermeable to acetyl-CoA under normal 
conditions. Thus citrate synthase activity can only be 
unmasked if the mitochondrial membrane is disrupted, e.g. 
by a detergent such as Triton X-100. Fig. 4B shows that 
addition of increasing concentrations of Triton X-100, 
indeed, leads to unmasking of citrate synthase activity, 
maximal activity being observed at a concentration of 
0.025% (w/v). Addition of palmitoyl-CoA up to 25 /zM 
did not elicit citrate synthase activity (Fig. 4A). Only at 
concentrations of 100 /zM partial unmasking of citrate 
synthase was observed (Fig. 4A). Fig. 4A also shows that 
palmitoyl-CoA had little effect on citrate synthase itself, 
since virtually no inhibitory effect of palmitoyl-CoA on 
citrate synthase was observed in sonicated cells (Fig. 4A). 
To complete this study we also investigated the effect 
of other acyl-CoA esters, with the aim of trying to estab- 
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lish some kind of relation between the effect on respira- 
tory-chain driven ATP synthesis, the length of the carbon 
chain and the degree of unsaturation of the ester. When 
synthesis of ATP was measured in the presence of differ- 
ent acyl-CoA esters at a fixed concentration of 15 /~M, it 
is clear that acyl-CoA esters with a chain-length of 14 to 
20 carbon atoms inhibit ATP synthesis dramatically (Fig. 
5A). The presence of a double bond, in general eads to 
slight reduction of the inhibitory potential (Fig. 5B). Fig. 
5A also shows that palmitoyl-L-carnitine does not have an 
inhibitory effect on ATP synthesis. 
4. Discussion 
In this paper we studied the effect of different acyl-CoA 
esters on oxidative phosphorylation using digitonin perme- 
abilized fibroblasts, in which oxidative phosphorylation 
can be studied relatively easily. Using succinate, in the 
presence of rotenone, as a respiratory substrate, we found 
that palmitoyl-CoA inhibits the synthesis of ATP from 
ADP and phosphate in a concentration-dependent manner. 
In principle the observed inhibition can be explained in 
several ways. Indeed the effect could be due to an uncou- 
pler-like effect of palmitoyI-CoA, a detergent-like effect or 
a more specific effect, notably at the level of the adenine 
nucleotide translocator. 
Uncouplers increase the permeability of the inner mito- 
chondrial membrane to protons, thereby reducing the elec- 
trochemical potential. As a consequence substrate oxida- 
tion per se will continue but ATP synthesis will drop. The 
finding that palmitoyl-CoA inhibits both the synthesis of 
ATP as well as the production of L-malate from succinate 
(Fig. 3), which directly reflects electron-transport through 
the respiratory chain, argues against an uncoupler-like 
effect of palmitoyl-CoA. 
Subsequent s udies in which the effect of palmitoyl-CoA 
was studied on the latency of citrate synthase, showed that 
the effect of palmitoyl-CoA cannot be ascribed to its 
potential detergent-like character, at least at concentrations 
below 25 /xM (Fig. 4). Earlier Pande and Blanchaer [35] 
studied the effect of palmitoyl-CoA on the rate of mito- 
chondrial respiration in the presence of ADP and con- 
cluded that the effect of palmitoyl-CoA was different from 
that of lauryl sulfate, an anionic detergent. 
Taken together, the results of Figs. 1-4 suggest hat 
palmitoyI-CoA is probably not affecting electron transport 
per se, although we have not formally excluded this, but 
rather the phosphorylation system. Since the phosphoryla- 
tion system is made up of the adenine nucleotide transloca- 
tor, the F~ Fo-ATPase and the phosphate/hydroxyl-carrier, 
inhibition by acyl-CoA esters may be due to an inhibitory 
effect on one or more of these steps. Under the conditions 
used in the present study acyl-CoA esters are unable to 
enter the mitochondrion by means of the carnitine-cycle, 
involving carnitine palmitoyltransferase I, the 
carnitine/acylcarnitine carrier and camitine palmitoyl- 
transferase II, due to the fact that carnitine was omitted 
from the incubation medium. This suggests that the ob- 
served inhibition of the phosphorylation system by acyl- 
CoA esters is probably due to an inhibitory effect on the 
phosphate/hydroxyl-carrier and/or ATP/ADP-carrier. 
Acyl-CoA esters are well known to inhibit the adenine 
nucleotide transport in isolated mitochondria [35,36]; see 
[37,38] for review) and liposomes [39]. Long-chain acyl- 
CoA esters like carboxyatractyloside, a specific inhibitor 
of the ATP/ADP carrier, inhibit the ATP/ADP carrier 
through a similar mechanism, probably affecting the same 
binding sites. Nevertheless, in contrast with carboxya- 
tractyloside, considered a non-competitive inhibitor with 
saturable binding sites, long-chain acyl-CoA esters, as 
atractyloside, have been described as competitive in- 
hibitors whose binding sites are not saturable [37,38,43,44]. 
Although acyl-CoA esters also inhibit the phosphate/hy- 
droxyl-carrier [40], the inhibition constants are more than 
100-fold higher in the case of the phosphate/hydroxyl-car- 
rier which suggests that the inhibition observed is primar- 
ily due to an inhibitory effect of acyl-CoA esters on the 
ATP/ADP-carrier. Non-esterified fatty acids also inhibit 
the ATP/ADP-carrier although the effective concentration 
for inhibition by fatty acids is 1-2 orders of magnitude 
higher as compared to the corresponding esterified fatty 
acyl-CoA esters [37,38]. 
In the intact cell most of the cytosolic (and mitochon- 
drial) acyl-CoAs are protein-bound. In this respect it is 
important o mention the presence of acyl-CoA binding 
proteins with high affinity for long-chain acyl-CoA esters 
in the cytosol of eukaryotic ells [45]. For this reason it 
remains to be established whether cytosolic acyl-CoA lev- 
els can reach levels high enough for inhibition to occur in 
intact systems. According to Soboll and coworkers long- 
chain fatty acyl-CoA esters also inhibit the ATP/ADP- 
carrier in intact cells, although this is disputed by other 
authors [41,42]. Finally, it should be stressed that acyl-CoA 
esters do not only inhibit the ATP/ADP-carrier from the 
cytosolic side but are also able to inhibit the carrier from 
the intramitochondrial side, although the K~-value is much 
lower as compared to the Ki-value found for inhibition by 
cytosolic acyl-CoAs [37,38]. In our experimental set-up we 
only studied the effect of extramitochondrial acyI-CoAs, 
since carnitine was omitted from the reaction medium 
thereby blocking the entrance of acyl-CoA esters into the 
mitochondrion. 
If the inhibition of the oxidative phosphorylation by 
palmitoyl-CoA and other long-chain acyl-CoA esters, as 
observed in this paper, is also occurring under in vivo 
conditions, this may well explain some of the findings in 
long-chain fatty acid oxidation disorders. Indeed, the lactic 
acidemia observed in patients with these kinds of disorders 
may be due to an impaired rate of pyruvate dehydrogena- 
tion, as a consequence of the high NADH/NAD + and 
ATP/ADP ratios in mitochondria, under conditions where 
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the ATP/ADP-translocator is inhibited, thus inhibiting 
flux through pyruvate dehydrogenase. As a consequence 
pyruvate is diverted into lactate. The mitochondrial 
NADH/NAD + ratio will be high due to the impaired rate 
of electron transport through the respiratory chain under 
conditions of a blocked adenine nucleotide translocator, 
whereas the intramitochondrial ATP/ADP ratio will be 
high since much less ATP is transported from the mito- 
chondria to the cytosol. The latter has been shown experi- 
mentally in isolated hepatocytes and perfused liver with 
carboxyatractyloside [40]. 
Finally, we studied the relationship between the inhibi- 
tion of ATP synthesis by long-chain acyl-CoA esters and 
the chain-length of the acyl-CoA ester. Inhibition of ATP 
synthesis was found to increase with increasing chain 
length, strongest inhibition being observed with acyl-CoA 
esters with a chain length of 14-20 carbon atoms (Fig. 5). 
Interestingly, very-long-chain acyl-CoA esters and 
medium-long-chain acyl-CoA esters are much less in- 
hibitory. The latter observation may explain the absence of 
lactic acidemia in MCAD-deficient patients. In accordance 
with data in the literature (see [37,38] for review) it was 
also found that for a given chain-length acyl-CoA ester the 
degree of unsaturation and the position of the double 
bound(s) does not play a major role with regard to their 
inhibitory potential (Fig. 5). Finally, it is interesting to note 
that palmitoyl-L-camitine is not affecting oxidative phos- 
phorylation (Fig. 5). Earlier studies by Pande and Blan- 
chaer [35] had already shown the same in rat heart mito- 
chondria. 
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